Balchem Co. (NASDAQ:BCPC - Free Report) - Research analysts at Sidoti Csr lowered their Q1 2025 earnings per share estimates for shares of Balchem in a research report issued to clients and investors on Wednesday, October 9th. Sidoti Csr analyst K. May now expects that the basic materials company will post earnings per share of $1.16 for the quarter, down from their prior estimate of $1.18. The consensus estimate for Balchem's current full-year earnings is $3.96 per share. Sidoti Csr also issued estimates for Balchem's Q2 2025 earnings at $1.18 EPS, Q3 2025 earnings at $1.21 EPS, Q4 2025 earnings at $1.20 EPS and FY2025 earnings at $4.75 EPS.
A number of other brokerages also recently issued reports on BCPC. HC Wainwright increased their target price on Balchem from $170.00 to $185.00 and gave the stock a "buy" rating in a research note on Wednesday, July 31st. StockNews.com downgraded Balchem from a "buy" rating to a "hold" rating in a research note on Monday, July 29th.
Check Out Our Latest Stock Analysis on Balchem
Balchem Stock Performance
Shares of BCPC stock traded up $2.03 during trading hours on Friday, reaching $172.21. 93,345 shares of the company's stock were exchanged, compared to its average volume of 106,979. The company has a market cap of $5.59 billion, a P/E ratio of 47.97, a price-to-earnings-growth ratio of 5.43 and a beta of 0.65. The company's 50 day moving average is $170.67 and its two-hundred day moving average is $161.04. Balchem has a 1 year low of $110.74 and a 1 year high of $186.03. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.83 and a quick ratio of 1.79.
Balchem (NASDAQ:BCPC - Get Free Report) last issued its earnings results on Friday, July 26th. The basic materials company reported $0.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.95 by $0.03. The business had revenue of $234.08 million during the quarter, compared to the consensus estimate of $241.26 million. Balchem had a return on equity of 10.94% and a net margin of 12.52%.
Hedge Funds Weigh In On Balchem
Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in Balchem by 3.8% during the first quarter. Vanguard Group Inc. now owns 3,935,935 shares of the basic materials company's stock worth $609,873,000 after buying an additional 144,423 shares in the last quarter. Conestoga Capital Advisors LLC boosted its holdings in shares of Balchem by 2.7% during the second quarter. Conestoga Capital Advisors LLC now owns 1,155,209 shares of the basic materials company's stock worth $177,844,000 after purchasing an additional 29,825 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Balchem by 0.9% during the second quarter. Dimensional Fund Advisors LP now owns 697,461 shares of the basic materials company's stock worth $107,372,000 after purchasing an additional 5,977 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Balchem by 1.2% during the second quarter. Bank of New York Mellon Corp now owns 277,475 shares of the basic materials company's stock worth $42,717,000 after purchasing an additional 3,279 shares during the last quarter. Finally, Congress Asset Management Co. MA boosted its holdings in shares of Balchem by 7.7% during the first quarter. Congress Asset Management Co. MA now owns 258,116 shares of the basic materials company's stock worth $39,995,000 after purchasing an additional 18,459 shares during the last quarter. Hedge funds and other institutional investors own 87.91% of the company's stock.
Insider Activity at Balchem
In related news, SVP Gunsteren Job Leonard Van sold 7,750 shares of the firm's stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $180.05, for a total value of $1,395,387.50. Following the completion of the transaction, the senior vice president now directly owns 8,540 shares of the company's stock, valued at $1,537,627. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.25% of the stock is currently owned by company insiders.
About Balchem
(
Get Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Read More
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
